Relief Therapeutics Company
Relief Therapeutics is a company that develops clinical-stage programs for respiratory disease treatments using natural molecules like peptides and proteins. Their lead drug candidate, RLF-100TM (aviptadil), is being tested in two late-stage clinical trials in the US for respiratory deficiency caused by COVID-19. The company holds a patent for potential formulations of RLF-100TM in the US and other countries.
Funding Status:
N/A
Headquarters:
Geneva
Founded Date:
2013
Investor Type:
N/A
Investment Stage:
N/A
Technology:
COVID
Employee Number:
N/A
Number Of Exists:
N/A
Industry:
PharmTech